

Join Us –

# Incubating and Launching New Life Science Companies

Tuesday, March 9, 2021

2:00 – 3:30 pm ET // 11:00 – 12:30 pm PT



## Moderator



### **Lewin Geffen** | Co-chair, Life Sciences and Venture Capital Practices

Lewis is Co-chair of both the Life Sciences Practice and the Venture Capital Practice at Mintz. As a corporate and licensing attorney focused on the life sciences, Lewis has over twenty five years of experience helping companies in the sector tackle strategic issues and complete complicated transactions. He serves as principal outside or general counsel to leading life science companies, advising management and directors as these companies raise capital, in-license and acquire technology and assets, collaborate or partner with others, and exit upon an IPO or strategic sale. In addition to day-to-day corporate counseling and strategic advice to his clients, Lewis regularly advises venture capital firms on a variety of major domestic and international business transactions, including financings, technology licensing, mergers and acquisitions and public offerings. Lewis graduated from UMass Amherst and received his law degree, cum laude, from Harvard Law School.

## Speakers



### **Nesson Bermingham, PhD** | Serial Entrepreneur and Investor

Nesson founded several companies including Triplet Therapeutics (currently President and CEO), Korro Bio (currently Executive Chair), and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” which he took from concept to IPO with 2 large partnering deals and over 200 employees when he left. He is also chair of the board of Fstar, a publicly listed immune-oncology company. Previously Nesson was a partner and venture partner with Atlas Venture, having worked with them over the past two decades across Europe and the US. He was also previously a managing partner at Omega Funds and independent advisor MerckSerono and CIRM. Nesson received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.



### **Nathaniel Brooks Horwitz** | Principal, Venture Team, RA Capital Management

Nathaniel is a Principal on the Venture Team at RA Capital Management and director on the boards of GentiBio and Santi Therapeutics. He also serves as an observer at Synthego, Quench Bio and two undisclosed companies. He previously served as an observer on the boards of Eliem Therapeutics, Clear Creek Bio and as chair and CEO of the Harvard Medical School spinout Nivien Therapeutics. Nathaniel graduated from Harvard University with an AB in Molecular and Cellular Biology, where his research focused on CRISPR as a tool for cardiovascular drug target discovery in the lab of Chad Cowan.



### **Deborah Palestrant, PhD** | Partner, Head of 4:59, 5AM Ventures

Deborah Palestrant, Ph.D., MBA joined 5AM Ventures in 2018 as Partner, Head of 5AM's 4:59 Initiative, its hands-on internal effort to discover, incubate, and fund breakthrough science. Dr. Palestrant has over 17 years of life sciences industry experience including drug discovery, company creation, operations, business development, and strategy, including 3 years at Third Rock Ventures where helped to build and launch Blueprint Medicines and Editas Medicine. Prior to joining 5AM, Dr. Palestrant was Vice President of Corporate Development & Strategy at Relay Therapeutics, where she executed business strategy including alliances, partnerships, and other collaborations and led communications. Prior to Relay, Dr. Palestrant led business development at Editas Medicine. Dr. Palestrant holds a Ph.D. in biochemistry and molecular biophysics from Columbia University, an MBA from Northeastern University, and was Damon Runyon Cancer Research Foundation Postdoctoral Fellow at The Scripps Research Institute.